What do systematic reviews say?

Chemotherapy vs chemotherapy alone

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 448 participants
  High

Chemotherapy vs placebo, best supportive care (BSC) or no treatment

Chemotherapy probably leads to higher serious adverse events compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.38 [1.2, 1.59]
  1 study · 503 participants
  Moderate

Chemotherapy vs chemotherapy alone

Chemotherapy showed no clear difference in tumour response rate (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 0.65 [0.34, 1.26]
  1 study · 179 participants
  Low
• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 0.89 [0.48, 1.67]
  1 study · 107 participants
  Low

Chemotherapy vs chemotherapy alone

It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.47 [0.56, 3.89]
  2 studies · 121 participants
  Very low

Chemotherapy vs chemotherapy alone

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 448 participants
  Moderate

Chemotherapy vs chemotherapy alone

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 70 participants
  Very low

Chemotherapy vs placebo, best supportive care (BSC) or no treatment

Chemotherapy showed no clear difference in tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 2.17 [0.63, 7.48]
  1 study · 435 participants
  Low

Chemotherapy vs placebo, best supportive care (BSC) or no treatment

Chemotherapy showed no clear difference in any adverse events compared with placebo, best supportive care (BSC) or no treatment (high certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.04 [1, 1.09]
  1 study · 503 participants
  High

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (high certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.55 [0.41, 0.73]
  3 studies · 781 participants
  High

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy probably leads to lower progression‐free survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.33 [0.19, 0.57]
  3 studies · 781 participants
  Moderate

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy showed no clear difference in serious adverse events compared with placebo, best supportive care (BSC) or no treatment (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 1.14 [0.95, 1.37]
  2 studies · 638 participants
  Low

Biological therapy vs placebo, best supportive care (BSC) or no treatment

Biological therapy may leads to higher tumour response rate compared with placebo, best supportive care (BSC) or no treatment (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  RR 5.12 [1.23, 21.27]
  3 studies · 687 participants
  Low

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

Intensification of prophylactic therapy guided by colonoscopy showed no clear difference in clinical recurrence ( compared with intensification guided by clinical recurrence (low certainty).

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  RR 0.82 [0.56, 1.18]
  1 study · 174 participants
  Low

Initiation of prophylactic therapy guided by colonoscopy vs initiation of prophylactic therapy immediately after surgery

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 63 participants
  GRADE not reported

Initiation of prophylactic therapy guided by colonoscopy vs initiation of prophylactic therapy immediately after surgery

The review found no eligible studies for this question.

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Initiation of prophylactic therapy guided by colonoscopy vs initiation of prophylactic therapy immediately after surgery

It is very uncertain whether initiation of prophylactic therapy guided by colonoscopy changes adverse effects ( compared with initiation of prophylactic therapy immediately after surgery (very low certainty).

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  RR 0.58 [0.42, 0.82]
  1 study · 63 participants
  Very low

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

Intensification of prophylactic therapy guided by colonoscopy may leads to lower endoscopic recurrence ( compared with intensification guided by clinical recurrence (low certainty).

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  RR 0.73 [0.56, 0.95]
  1 study · 174 participants
  Low

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  504 participants
  Very low

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 174 participants
  GRADE not reported

Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence

The review found no eligible studies for this question.

• Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found